Successful Treatment with Brigatinib after Alectinib-Induced Hemolytic Anemia in Patients with Metastatic Lung Adenocarcinoma—A Case Series

Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor used in the treatment of advanced ALK-rearrangement positive non-small-cell lung cancer (NSCLC). Many tolerable adverse events were reported with the use of Alectinib; nevertheless, hemolytic anemia was not mentioned in the...

Full description

Bibliographic Details
Published in:Current Oncology
Main Authors: Rola El Sayed, Mustapha Tehfe, Normand Blais
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Subjects:
non-small-cell lung cancer
alectinib
oxidative stress
hemolytic anemia
Online Access:https://www.mdpi.com/1718-7729/30/1/41

Internet

https://www.mdpi.com/1718-7729/30/1/41

Similar Items